Page 2 - Enteric Hyperoxaluria News Today

/PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported...

Synlogic Reports First Quarter Financial Results and Provides Business Update - Proof of concept studies for co-lead metabolic programs SYNB1618 in PKU and SYNB8802 in Enteric Hyperoxaluria on track for 2H 2021 readouts - - $94.4 million in cash, cash equivalents, and short-term investments as of March 31 plus April financing of $32.6 million (net) enables runway extension to 2H 2023 - - Management to host conference call and webcast at 8:30 a.m. ET today - News provided by Share this article S...

Synlogic Announces Pricing of Public Offering of Common Stock News provided by Share this article CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $3.00 per share. The gross proceeds to Synlogic from the offering, before deducting the und...

Synlogic Announces Proposed Public Offering of Common Stock News provided by Share this article Share this article CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Synlogic. Synlogic intends to grant the underwr...

Synlogic to Present at Upcoming Virtual Banking and Industry Conferences News provided by Share this article Share this article CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan, M.B. Ch.B., Synlogics President and Chief Executive Officer, and other members of the executive team will present at the following virtual banking and industr...

/PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced...

Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory - Synlogic to provide bioprocess and manufacturing in joint effort to engineer novel investigational medicines to address battle fatigue - News provided by Share this article Share this article CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of syntheti...

Acorda Rises On Restructuring, ALXN Pauses COVID-19 Trial, SYBX On Watch Read on. 1. Acorda Rises on Corporate Restructuring Shares of Acorda Therapeutics Inc. (ACOR) jumped over 44% on Wednesday, on news of the company agreeing to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent, Inc. (CTLT) for $80 million in cash. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinsons...

Synlogic Outlines Upcoming Clinical Milestones - Clinical proof of concept data in 2021 anticipated across multiple programs - News provided by Share this article CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical milestones for 2021 and provided an overview of recent progress. "With three programs in clinical trials, multiple proof of...